- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Transition in United Kingdom
Total 406 results
-
University of MichiganCompletedUrinary Tract Urothelial CarcinomaUnited States
-
Incyte CorporationMerck Sharp & Dohme LLCCompletedUC (Urothelial Cancer)United States, Spain, Hungary, Israel, United Kingdom, Korea, Republic of, Taiwan, Denmark, France, Netherlands, Italy, Canada, Japan, Turkey, Germany, Ireland, Australia, Russian Federation
-
Merck Sharp & Dohme LLCActive, not recruitingUrothelial CarcinomaAustralia, United States, Chile, Denmark, Israel, Korea, Republic of, Spain
-
Principia Biopharma, a Sanofi CompanyTerminatedSolid Tumors | Metastatic Urothelial Carcinoma & Renal Pelvis & UreterSpain, United States
-
Mamta ParikhNational Cancer Institute (NCI); Karyopharm Therapeutics IncRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial CarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterGlaxoSmithKlineTerminated
-
University of Texas Southwestern Medical CenterRecruitingUrothelial Cancer of Renal Pelvis | Urothelial Carcinoma UreterUnited States
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI); Cancer and Leukemia Group BCompletedBladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral CancerUnited States
-
Eli Lilly and CompanyCompletedUrothelial CarcinomaSpain, United States, Poland, Romania, Taiwan, Ukraine, Netherlands, Mexico, Japan, France, Germany, Belgium, Greece, Russian Federation, Turkey, Canada, Israel, Italy, United Kingdom, Denmark, Korea, Republic of, Australia, Hungary
-
Merck Sharp & Dohme LLCEisai Inc.Active, not recruitingUrothelial CarcinomaHungary, United States, Argentina, Australia, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
-
Astellas Pharma Global Development, Inc.Seagen Inc.Approved for marketingLocally Advanced or Metastatic Urothelial Carcinoma (UC)United States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal NeoplasmUnited States
-
University of UtahExelixisActive, not recruitingBladder Cancer | Metastatic Urothelial CarcinomaUnited States
-
University of Michigan Rogel Cancer CenterPfizerTerminatedBladder CancerUnited States
-
Memorial Sloan Kettering Cancer CenterUniversity of Chicago; Genentech, Inc.; Ohio State University; TargosActive, not recruitingUrothelial Carcinoma | Locally Advanced | UnresectableUnited States
-
University of Michigan Rogel Cancer CenterTerminatedBladder Cancer | Urothelial CancerUnited States
-
xCuresTerminatedTransitional Cell Carcinoma | Bladder Cancer | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR2 Amplification | Bladder Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Refractory Bladder Carcinoma | Refractory Bladder Urothelial Carcinoma and other conditionsUnited States
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar TherapeuticsRecruitingLocally Advanced or Metastatic Urothelial CarcinomaKorea, Republic of, United States, Taiwan, Australia, United Kingdom, France, Greece, Italy, Belgium, Spain, Canada, Denmark, Germany
-
University of UtahNational Cancer Institute (NCI)RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid VariantUnited States
-
Acerta Pharma BVMerck Sharp & Dohme LLCCompletedMetastatic Urothelial CarcinomaUnited States
-
BioNTech US Inc.Bristol-Myers SquibbCompletedMelanoma | Carcinoma, Non-Small-Cell Lung | Lung Cancer | Urinary Bladder Cancer | Skin Cancer | Transitional Cell Carcinoma of the Bladder | Malignant Melanoma | Bladder TumorsUnited States
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)CompletedBladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedOvarian Cancer | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Adenocarcinoma | Ovarian... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI); ExelixisRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma With Squamous DifferentiationUnited States
-
Bristol-Myers SquibbPierre Fabre MedicamentCompletedKidney Neoplasms | Transitional Cell Carcinoma | Bladder Cancer | Bladder Neoplasms | Ureter Neoplasms | Neoplasm, BladderUnited States, Spain, Italy, Canada, Indonesia, Singapore, Australia, Austria, France, Greece, Korea, Republic of, Philippines, Sweden, Switzerland, Thailand
-
ALX Oncology Inc.RecruitingBladder Cancer | Urothelial CarcinomaUnited States
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)CompletedBladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral CancerUnited States, Puerto Rico, South Africa
-
Memorial Sloan Kettering Cancer CenterCompletedCancer | Urothelial Carcinoma | Myeloproliferative DisorderUnited States
-
Apexigen America, Inc.CompletedMelanoma | Cancer | Head and Neck Cancer | NSCLC | Urothelial Carcinoma | MSI-HUnited States
-
University of UtahUniversity of MichiganEnrolling by invitationPneumonia | Urinary Tract Infection | Antibiotic Stewardship | Care TransitionUnited States
-
Hoffmann-La RocheCompletedUrothelial CarcinomaSpain, United States, Korea, Republic of, Canada, United Kingdom, Czechia, Australia, Belgium, Brazil, China, Estonia, Finland, Greece, Hong Kong, Italy, Poland, Portugal, Slovenia, Mexico, Georgia, Russian Federation, Singapore, Th... and more
-
HiberCell, Inc.CovanceTerminatedA Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)Clear Cell Renal Cell Carcinoma | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Colo-rectal Cancer | Transitional Cell Carcinoma of the Bladder | Other Solid TumorsUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedHigh Grade Upper Tract Urothelial CarcinomaUnited States
-
DendreonTerminatedUrothelial CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial CarcinomaUnited States
-
BayerActive, not recruitingUrothelial CarcinomaUnited States, Korea, Republic of, Japan, Germany, Italy, Spain, Austria, France
-
Alison GalbraithHarvard School of Public Health (HSPH); Agency for Healthcare Research and... and other collaboratorsCompletedChronic Obstructive Pulmonary Disease | Hospital Readmission | Congestive Heart Failure | Post-discharge Care TransitionsUnited States
-
Medical University of South CarolinaTerminated
-
Seagen Inc.Merck Sharp & Dohme LLC; RemeGen Co., Ltd.RecruitingUrothelial CarcinomaUnited States, Canada, Australia, Singapore
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingProstate Cancer | Urothelial Carcinoma | Stage IV Bladder Urothelial CarcinomaUnited States
-
Flare Therapeutics Inc.RecruitingAdvanced Solid Tumors Cancer | Advanced Urothelial Carcinoma | Open Label | Oral Drug AdministrationUnited States
-
University Health Network, TorontoNational Cancer Institute (NCI)Completed
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUrinary Bladder Neoplasms | Bladder Cancer | Urothelial CarcinomaUnited States
-
University of Texas Southwestern Medical CenterCompletedMelanoma | Urothelial Carcinoma | Cervical Carcinoma in SituUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnInfiltrating Bladder Urothelial Carcinoma | Stage II Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma | Stage III Bladder Urothelial CarcinomaUnited States
-
Infinity Pharmaceuticals, Inc.Bristol-Myers SquibbCompletedSolid Tumor | Bladder Cancer | Advanced Cancer | Urothelial CarcinomaFrance, Spain, United States, Italy, Czechia, Poland, Serbia
-
Icahn School of Medicine at Mount SinaiCelgeneTerminatedUrinary Bladder NeoplasmsUnited States
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States